Objective: To collect information on biobanking facilities in low- and middle-income countries (LMICs) as a first step towards establishing an LMIC biobank and cohort building network (BCNet) to support research, with a focus on cancer control. Method: Sixty centres were identified from sources including cancer centres, universities, hospitals, and public health facilities and invited to participate in a survey between December 2012 and March 2013. Results: Of the 27 centres (45%) that responded, most have existed for <10 years. They store between 1,000 and 1,000,000 research samples as well as samples remaining after clinical diagnosis. Sample storage is mostly in freezers, although 45% (9/20) of the centres do not have regular access to electricity. Biobank managers, sample management systems, and mechanisms for follow-up using linkages are uncommon. Many (80%; 21/26) of the centres have regulations to govern research, but regulations for the use of biobank resources (samples and data) are not well developed. Conclusions: Biobanking facilities are being developed in LMICs. Shortcomings in international visibility, sample sharing regulations, standardization, quality assurance, and sample management systems could be alleviated by international networking. Stakeholders need to work together to increase access to high-quality biological resources for scientific research.

Keywords:
Biobank, Low- and middle-income countries, Biobank and Cohort Building, Ethical, legal, and social issues
1.
OECD Best Practice Guidelines for Biological Resource Centres. Paris, OECD, 2012.
2.
Knoppers BM, Zawati MH, Kirby ES: Sampling populations of humans across the world: ELSI issues. Annu Rev Genomics Hum Genet 2012;13:395-413.
3.
Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G: Should donors be allowed to give broad consent to future biobank research? Lancet Oncol 2006;7:266-269.
4.
Collins R: What makes UK Biobank special? Lancet 2012;379:1173-1174.
5.
Hainaut P, Vozar B, Rinaldi S, Riboli E, Caboux E: The European prospective investigation into cancer and nutrition biobank. Methods Mol Biol 2011;675:179-191.
6.
Kaiser J: Biobanks. Population databases boom, from Iceland to the U.S. Science 2002;298:1158-1161.
7.
Peakman T, Elliott P: Current standards for the storage of human samples in biobanks. Genome Med 2010;2:72.
8.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide (GLOBOCAN 2012 v1.0). IARC CancerBase 2013;11:video.
9.
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
10.
Fox MP, Maskew M, MacPhail AP, Long L, Brennan AT, Westreich D, MacLeod WB, Majuba P, Sanne IM: Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol 2013;42:430-439.
11.
Sirugo G, Schim van der LM, Sam O, Nyan O, Pinder M, Hill AV, Kwiatkowski D, Prentice A, de Toma C, Cann HM, Diatta M, Jallow M, Morgan G, Clarke M, Corrah T, Whittle H, McAdam K: A national DNA bank in the Gambia, West Africa, and genomic research in developing countries. Nat Genet 2004;36:785-786.
12.
Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, Masimirembwa CM: Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 2008;16:780-783.
13.
Hellings J, Schrooten W, Klazinga N, Vleugels A: Challenging patient safety culture: survey results. Int J Health Care Qual Assur 2007;20:620-632.
14.
Staunton C, Moodley K: Challenges in biobank governance in Sub-Saharan Africa. BMC Med Ethics 2013;14:35.
15.
Calzolari A, Napolitano M, Bravo E: Review of the Italian current legislation on research biobanking activities on the eve of the participation of national biobanks' network in the legal consortium BBMRI-ERIC. Biopreserv Biobank 2013;11:124-128.
16.
Riegman PH, de Jong BW, Llombart-Bosch A: The Organization of European Cancer Institute Pathobiology Working Group and its support of European biobanking infrastructures for translational cancer research. Cancer Epidemiol Biomarkers Prev 2010;19:923-926.
17.
Yuille M, van Ommen GJ, Brechot C, Cambon-Thomsen A, Dagher G, Landegren U, Litton JE, Pasterk M, Peltonen L, Taussig M, Wichmann HE, Zatloukal K: Biobanking for Europe. Brief Bioinform 2008;9:14-24.
18.
Lawlor R, Sluss P, Langer R, Sughayer M, Igbe M, Saddiqui K, De Blasio P, Duma B, Mendy M, Chabannon C, Muntasser I: European, Middle Eastern, and African Society for Biopreservation and Biobanking (ESBB). 2012 Conference Session on Biobanking in Emerging Countries. Biopreserv Biobank 2013;11:176-181.
19.
Moore HM, Kelly A, McShane LM, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Transfusion 2013;53:e1.
20.
Betsou F, Lehmann S, Ashton G, Barnes M, Benson EE, Coppola D, DeSouza Y, Eliason J, Glazer B, Guadagni F, Harding K, Horsfall DJ, Kleeberger C, Nanni U, Prasad A, Shea K, Skubitz A, Somiari S, Gunter E: Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev 2010;19:1004-1011.
21.
Dhai A, Mahomed S: Biobank research: time for discussion and debate. S Afr Med J 2013;103:225-227.
22.
Igbe MA, Adebamowo CA: Qualitative study of knowledge and attitudes to biobanking among lay persons in Nigeria. BMC Med Ethics 2012;13:27.
23.
Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, Kumar R, Roy S, Suraweera W, Bray F, Mallath M, Singh PK, Sinha DN, Shet AS, Gelband H, Jha P: Cancer mortality in India: a nationally representative survey. Lancet 2012;379:1807-1816.
24.
Gudleviciene Z, Smailyte G, Mickonas A, Pikelis A: Prevalence of human papillomavirus and other risk factors in Lithuanian patients with head and neck cancer. Oncology 2009;76:205-208.
25.
Sughayer MA, Abdelhadi M, Abdeen G, Otay L, Dayeh T: Human papillomavirus genotypes in invasive cervical cancer in Jordan. Int J Gynaecol Obstet 2010;108:74-75.
26.
Al-Masri M, Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M: Phyllodes tumor of the breast: role of CD10 in predicting metastasis. Ann Surg Oncol 2012;19:1181-1184.
27.
Sughayer MA, Zakarneh L, Abu-Shakra R: Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res 2009;15:423-427.
28.
Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, O'Connell DL, Whiteman DC, Brennan P, Malekzadeh R, Pawlita M, Dawsey SM, Waterboer T; InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012;104:147-158.
29.
McDermid JM, Hennig BJ, van der SM, Hill AV, Whittle HC, Jaye A, Prentice AM: Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study. BMC Infect Dis 2013;13:48.
30.
Dominguez-Salas P, Cox SE, Prentice AM, Hennig BJ, Moore SE: Maternal nutritional status, C(1) metabolism and offspring DNA methylation: a review of current evidence in human subjects. Proc Nutr Soc 2012;71:154-165.
31.
Horikoshi M, Yaghootkar H, Mook-Kanamori DO, et al: New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet 2013;45:76-82.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.